Thr2156

Site Information
tVtPPtPtLLsPKGS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4694930

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 2 ) , Jurkat (T lymphocyte) ( 1 , 4 ) , NCI-H3255 (pulmonary) ( 3 )

Upstream Regulation
Treatments:	angiotensin_2 ( 2 )

References
1	Guo A (2011) CST Curation Set: 12019; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
2	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
3	Possemato A (2009) CST Curation Set: 7317; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
4	Possemato A (2008) CST Curation Set: 4737; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info